Protease inhibitor could help prevent alzheimer's

April 10, 2000

Principle similar to AIDS treatment

Researchers have succeeded for the first time in designing a chemical that -- in test tube studies -- can stop the chain reaction that leads to Alzheimer's disease, a finding reported in the current (April 12) print edition of the Journal of the American Chemical Society, published by the American Chemical Society, the world's largest scientific society.

Chemist Jordan Tang, Ph.D., has created a highly potent protease inhibitor for a human brain enzyme called memapsin 2. This could be a step forward in finding a drug for treating the now-incurable disease, he said. Although the inhibitor has yet to be made into a drug or tested outside the laboratory, the discovery holds great promise, according to the researcher. In principle it is similar to a treatment currently used successfully to combat the AIDS virus, Tang continued.

The work differs from other Alzheimer's research because it prevents the beginnings of the disease rather than treating the symptoms or coping with the damaged cells.

"I think (memapsin 2) is one of the most promising targets for Alzheimer's disease to come along that can be translated into treatments," said Tang, head of the protein studies program at the Oklahoma Medical Research Foundation. "We have accumulated a lot of knowledge on the proteases like memapsin 2. We thought it should be possible to design very potent inhibitors using this knowledge. Now we know it works."

Alzheimer's is a genetic defect that causes a loss of brain function, primarily among elderly people. There are an estimated 4 million diagnosed cases in the United States, according to the National Institute of Aging. Approximately 10 percent of the U.S. population have inherited genetic mutations that may lead to the disease, according to the Alzheimer's Disease Education and Referral Center.

Among reported cases of Alzheimer's, the remaining 90 percent are "sporadic," meaning they have no familial connection. All Alzheimer's cases, however, have a common basis: the accumulation of a chemical that kills brain cells and leads to dementia.

In theory, memapsin 2 will stop the production of the killer chemical, known as beta-amyloid, thus stopping the progression of Alzheimer's disease. It essentially cuts the larger protein known as amyloid precursor protein (APP) in half and prevents it from affecting other brain cells.

"The production of (beta-amyloid) to cause Alzheimer's disease is a mistake in the cell," Tang said. "If we can prevent the cell from making this mistake, then we can stop the progression and maybe even the onset of Alzheimer's disease."

Tang and his research team initially discovered memapsin 2 as a possible new human protease while searching the human genome sequence database. They eventually connected its function to Alzheimer's, though they originally were looking at a protease found in human immunodeficiency virus (the virus that leads to AIDS). Their research experience with similar compounds and the HIV inhibitor contributed to the design of memapsin 2, Tang said.

The next step in the research, according to Tang, is to shrink the chemical compound into a size usable for drug treatments. Such a step should be feasible, he said, but will likely take five years or more. Only after continuing studies in the laboratory can animal and human testing begin.

"If the ultimate inhibitor drug has low side effects, it should permit these people to live the rest of their lives normally," Tang said.
-end-
A nonprofit organization with a membership of 161,000 chemists and chemical engineers, the American Chemical Society (www.acs.org) publishes scientific journals and databases, convenes major research conferences, and provides educational, science policy and career programs in chemistry. Its main offices are in Washington, D.C., and Columbus, Ohio.

American Chemical Society

Related Aids Articles from Brightsurf:

Developing a new vaccination strategy against AIDS
Infection researchers from the German Primate Center (DPZ) -- Leibniz Institute for Primate Research have in cooperation with international colleagues tested a new vaccination strategy against the HIV-related simian immunodeficiency virus (SIV) in rhesus monkeys.

HIV-AIDS: Following your gut
Researchers find a way to reduce replication of the AIDS virus in the gastrointestinal tract.

A path toward ending AIDS in the US by 2025
Using prevention surveillance data to model rates of HIV incidence, prevalence and mortality, investigators at Brigham and Women's Hospital and Johns Hopkins Bloomberg School of Public Health set targets, specifically a decrease in new infections to 21,000 by 2020 and to 12,000 by 2025, that would mark a transition toward ending the HIV/AIDS epidemic.

What does it take for an AIDS virus to infect a person?
Researchers examined the characteristics of HIV-1 strains that were successful in traversing the genital mucosa that forms a boundary to entry by viruses and bacteria.

How AIDS conquered North America
A new technique that allowed researchers to analyze genetic material from serum samples of HIV patients taken before AIDS was known provides a glimpse of unprecedented detail into the beginnings of the AIDS epidemic in North America.

New research could help build better hearing aids
Scientists at Binghamton University, State University of New York want to improve sensor technology critical to billions of devices made every year.

NY State Department of Health AIDS Institute funds HIV/AIDS prevention in high-risk youth
NewYork-Presbyterian's Comprehensive Health Program and Project STAY, an initiative of the Harlem Heath Promotion Center (HHPC) at Columbia University's Mailman School of Public Health has received two grants totaling more than $3.75 million from the New York State Department of Health AIDS Institute for their continued efforts to prevent HIV/AIDS in at-risk youth.

A new way to nip AIDS in the bud
When new HIV particles bud from an infected cell, the enzyme protease activates to help the viruses infect more cells.

AIDS research prize for Warwick academic
A researcher at the University of Warwick has received international recognition for his contribution to AIDS research.

Insects inspire next generation of hearing aids
An insect-inspired microphone that can tackle the problem of locating sounds and eliminate background noise is set to revolutionize modern-day hearing aid systems.

Read More: Aids News and Aids Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.